The Journal of Experimental Medicine
Imagine Science Film Festival
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 6 August 2001. doi:10.1084/jem.194.3.321
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ji, H.
Right arrow Articles by Mathis, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ji, H.
Right arrow Articles by Mathis, D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© The Rockefeller University Press, 0022-1007/2001/8/321/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 3, August 6, 2001 321-330


Original Article

Genetic Influences on the End-Stage Effector Phase of Arthritis

Hong Jia,b,c, Dominique Gauguierd, Koichiro Ohmuraa,b,c, Antonio Gonzaleza,b,c, Veronique Duchatellef, Patrick Danoya,b,c, Henri-Jean Garchong, Claude Degottf, Mark Lathrope, Christophe Benoista,b,c, and Diane Mathisa,b,c
a Section on Immunology and Immunogenetics, Joslin Diabetes Center, Boston, MA 02115
b Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215
c Institut de Génétique et de Biologie Moléculaire et Cellulaire (Centre National de la Recherche Scientifique (CNRS)/Institut National de la Santé et de la Recherche Médicale (INSERM)/Université Louis Pasteur), 67404 Strasbourg, France
d The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK
e Centre National de Genotypage, CP 5721, 91057 Evry Cedex, France
f Service d'Anatomie et de Cytologie Pathologique, Hopital Beaujon, 92118 Clichy Cedex, France
g INSERM U25, Hopital Necker, Paris, France 75015

Correspondence to: Diane Mathis, Joslin Diabetes Center, One Joslin Pl., Boston, MA 02215. Tel:617-264-2745 Fax:617-264-2744 E-mail:cbdm{at}joslin.harvard.edu.

K/BxN T cell receptor transgenic mice are a model of inflammatory arthritis, most similar to rheumatoid arthritis, that is critically dependent on both T and B lymphocytes. Transfer of serum, or just immunoglobulins, from arthritic K/BxN animals into healthy recipients provokes arthritis efficiently, rapidly, and with high penetrance. We have explored the genetic heterogeneity in the response to serum transfer, thereby focussing on the end-stage effector phase of arthritis, leap-frogging the initiating events. Inbred mouse strains showed clear variability in their responses. A few were entirely refractory to disease induction, and those which did develop disease exhibited a range of severities. F1 analyses suggested that in most cases susceptibility was controlled in a polygenic additive fashion. One responder/nonresponder pair (C57Bl/6 x NOD) was studied in detail via a genome scan of F2 mice; supplementary information was provided by the examination of knock-out and congenic strains. Two genomic regions that are major, additive determinants of the rapidity and severity of K/BxN serum-transferred arthritis were highlighted. Concerning the first region, on proximal chromosome (chr)2, candidate assignment to the complement gene C5 was confirmed by both strain segregation analysis and functional data. Concerning the second, on distal chr1, coinciding with the Sle1 locus implicated in susceptibility to lupus-like autoimmune disease, a contribution by the fcgr2 candidate gene was excluded. Two other regions, on chr12 and chr18 may also contribute to susceptibility to serum-transferred arthritis, albeit to a more limited degree. The contributions of these loci are additive, but gene dosage effects at the C5 locus are such that it largely dominates. The clarity of these results argues that our focus on the terminal effector phase of arthritis in the K/BxN model will bear fruit.

Key Words: rheumatoid arthritis, animal model, genetics, complement, autoimmunity


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS